CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $2.24B, above the global median of $1.15B
- FinancialsAltman Z-Score 0.14: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.24BUSDvs all stocks (USD)
Revenue (TTM)
870.56MUSDvs all stocks (USD)
Profit Margin
-69.94%vs Medical Devices peers
Beta
1.79xvs all stocks
52-Week Change
114.86%vs all stocks
Market Capitalization
2.24BUSDvs all stocks (USD)
Enterprise Value
2.87BUSDvs all stocks (USD)
Forward P/E
34.23xvs Medical Devices peers
Price to Sales (TTM)
2.57xvs Medical Devices peers
Price to Book (MRQ)
1.06xvs Medical Devices peers
Enterprise to Revenue
3.30xvs Medical Devices peers
Enterprise to EBITDA
35.33xvs Medical Devices peers
Gross Margin
46.88%vs Medical Devices peers
Profit Margin
-69.94%vs Medical Devices peers
Operating Margin
-1.56%vs Medical Devices peers
Return on Assets (TTM)
-0.61%vs Medical Devices peers
Return on Equity (TTM)
-25.57%vs Medical Devices peers
Revenue (TTM)
870.56MUSDvs all stocks (USD)
Revenue per Share (TTM)
4.01USDUpdated Jul 19, 2026Quarterly Revenue Growth
-4.40%vs Medical Devices peers
Gross Profit (TTM)
393.58MUSDvs all stocks (USD)
EBITDA (TTM)
79.15MUSDvs all stocks (USD)
Net Income (TTM)
-608.84MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-4.43%vs Medical Devices peers
Operating Cash Flow (TTM)
69.44MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
19.47MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
894.66MUSDFY2025 · May 31, 2025Cost of Goods Sold
473.29MUSDFY2025 · May 31, 2025Gross Profit
421.38MUSDFY2025 · May 31, 2025Operating Income
-1.68MUSDvs all stocks (USD)
Pre-tax Income
-1.13BUSDFY2025 · May 31, 2025Income Tax Expense
-41.07MUSDFY2025 · May 31, 2025Net Income
-1.09BUSDFY2025 · May 31, 2025EBIT
-1.06BUSDFY2025 · May 31, 2025EBITDA (Income Statement)
123.50MUSDFY2025 · May 31, 2025Research & Development
21.09MUSDFY2025 · May 31, 2025Selling, General & Administrative
401.96MUSDFY2025 · May 31, 2025Non-operating Interest Income
3.11MUSDFY2025 · May 31, 2025Non-operating Interest Expense
71.62MUSDFY2025 · May 31, 2025EPS (Basic)
-5.03USDFY2025 · May 31, 2025EPS (Diluted)
-5.03USDFY2025 · May 31, 2025Basic Shares Outstanding
217.04MSharesFY2025 · May 31, 2025Diluted Shares Outstanding
217.04MSharesFY2025 · May 31, 2025Net Income from Continuing Operations
-1.09BUSDFY2025 · May 31, 2025Operating Cash Flow
-1.01BUSDFY2025 · May 31, 2025Free Cash Flow
-1.11BUSDFY2025 · May 31, 2025Cash & Cash Equivalents (End of Period)
129.00MUSDFY2025 · May 31, 2025Income Tax Paid
26.54MUSDFY2025 · May 31, 2025Interest Paid
68.14MUSDFY2025 · May 31, 2025Starting Profit (CF Statement)
-1.09BUSDFY2025 · May 31, 2025Depreciation & Amortization
125.67MUSDFY2025 · May 31, 2025Deferred Taxes (CF)
-57.78MUSDFY2025 · May 31, 2025Stock-based Compensation
17.29MUSDFY2025 · May 31, 2025Other Non-cash Items
380.00KUSDFY2025 · May 31, 2025Change in Accounts Receivable (CF)
11.64MUSDFY2025 · May 31, 2025Change in Accounts Payable (CF)
-402.00KUSDFY2025 · May 31, 2025Change in Other Assets/Liabilities
-15.76MUSDFY2025 · May 31, 2025Capital Expenditures
-99.52MUSDFY2025 · May 31, 2025Net Acquisitions
0.00USDFY2025 · May 31, 2025Purchase of Investments
0.00USDFY2025 · May 31, 2025Sale of Investments
325.00KUSDFY2025 · May 31, 2025Net Investing Cash Flow
-99.19MUSDFY2025 · May 31, 2025Long-term Debt Issuance
550.00MUSDFY2025 · May 31, 2025Long-term Debt Payments
-550.32MUSDFY2025 · May 31, 2025Other Financing Charges
-3.52MUSDFY2025 · May 31, 2025Net Financing Cash Flow
-3.84MUSDFY2025 · May 31, 2025Shares Outstanding
217.67MSharesUpdated Jul 19, 2026Float Shares
216.47MSharesUpdated Jul 19, 2026Shares Short
10.49MSharesUpdated Jul 19, 2026Short Ratio
4.73daysvs all stocks
Short % of Shares Outstanding
6.44%vs all stocks
% Held by Insiders
0.95%vs all stocks
% Held by Institutions
113.88%vs all stocks
Total Cash (MRQ)
159.90MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7350USDUpdated Jul 19, 2026Total Debt (MRQ)
795.10MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3782xvs Medical Devices peers
Current Ratio (MRQ)
3.92xvs Medical Devices peers
Book Value per Share (MRQ)
9.66USDUpdated Jul 19, 2026Total Assets
3.44BUSDvs all stocks (USD)
Total Current Assets
576.94MUSDFY2025 · May 31, 2025Total Liabilities
1.37BUSDFY2025 · May 31, 2025Total Non-current Assets
2.87BUSDFY2025 · May 31, 2025Total Non-current Liabilities
1.20BUSDFY2025 · May 31, 2025Total Current Liabilities
174.01MUSDFY2025 · May 31, 2025Cash & Cash Equivalents
129.00MUSDFY2025 · May 31, 2025Other Short-term Investments
0.00USDFY2025 · May 31, 2025Accounts Receivable
153.38MUSDFY2025 · May 31, 2025Inventory
190.86MUSDFY2025 · May 31, 2025Accounts Payable
79.61MUSDFY2025 · May 31, 2025Short-term Debt
19.30MUSDFY2025 · May 31, 2025Deferred Revenue
5.56MUSDFY2025 · May 31, 2025Other Current Liabilities
38.74MUSDFY2025 · May 31, 2025Long-term Debt
874.81MUSDFY2025 · May 31, 2025Other Non-current Liabilities
42.85MUSDFY2025 · May 31, 2025Common Stock (Book)
34.73MUSDFY2025 · May 31, 2025Retained Earnings
-536.42MUSDFY2025 · May 31, 2025Total Shareholders' Equity
2.07BUSDvs all stocks (USD)
52-Week Low
4.56USDUpdated Jul 19, 202652-Week High
11.43USDUpdated Jul 19, 202652-Week Change
114.86%vs all stocks
Beta
1.79xvs all stocks
50-Day MA
9.15USDUpdated Jul 19, 2026200-Day MA
8.47USDUpdated Jul 19, 2026Avg 10-Day Volume
1.55MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.89MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.80USDUpdated Jul 19, 2026Other Income / Expense
-3.60MUSDFY2025 · May 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.47Profit Margin: -0.70
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.92Altman Z-Score: 0.14
Financial Health
Altman Z-Score 0.14: distress zoneCritical
Altman Z-Score: 0.14
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $2.24B, above the global median of $1.15BNotable
Market cap (USD): 2,235,502,131Global Median: 1,146,734,693.424
Revenue is $870.56M, above the global median of $520.53MNotable
Revenue (USD): 870,561,024Global Median: 520,528,949.311
Levered free cash flow is $19.47M, above the global median of $16.24MNotable
Levered free cash flow (USD): 19,474,124Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Zai Lab Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
Iovance Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sionna Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Granules India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pfizer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nanobiotix S.A.
Tier 1ProductionApproval-Gated PipelineRule
Fujian Cosunter Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Oxford Nanopore Technologies plc
Tier 1ProductionApproval-Gated PipelineFlowInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Amadeus IT Group S.A.
1 interpretationIntangible Concentration
Gray Television, Inc.
1 interpretationIntangible Concentration
Halozyme Therapeutics Inc.
1 interpretationIntangible Concentration